Oxytocin intranasal - Trigemina

Drug Profile

Oxytocin intranasal - Trigemina

Alternative Names: TI-001; TI-114

Latest Information Update: 31 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trigemina
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Migraine
  • No development reported Headache; Trigeminal neuralgia

Most Recent Events

  • 29 Mar 2016 Trigemina completes a phase-II trial in Migraine in Australia, Chile and New Zealand (Intranasal)(NCT01839149) before December 2015
  • 15 Mar 2016 Biomarkers information updated
  • 11 Aug 2015 Trigemina has patent protection for TI 114 in USA and other countries around world (Trigemina website, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top